Raltitrexed Treatment and Inflammation in Colorectal Cancer
Author Information
Author(s): Österlund P, Orpana A, Elomaa I, Repo H, Joensuu H
Primary Institution: Helsinki University Central Hospital
Hypothesis
Does raltitrexed treatment trigger a systemic inflammatory reaction in colorectal cancer patients?
Conclusion
Colorectal cancer patients treated with raltitrexed often develop drug-related systemic inflammation, which can be mistaken for infection.
Supporting Evidence
- 75% of patients experienced fever after raltitrexed treatment.
- 94% of patients reported fatigue and elevated serum CRP levels.
- Systemic inflammation was assessed using a composite score based on various inflammatory markers.
Takeaway
When patients with colorectal cancer take a medicine called raltitrexed, they can get fevers and feel very tired, which might be caused by the medicine itself and not an infection.
Methodology
The study involved longitudinal and cross-sectional analyses of patients treated with raltitrexed and carmofur, measuring inflammatory markers and symptoms.
Potential Biases
Potential bias due to the non-randomized design and the possibility of unverified infections.
Limitations
The study was non-randomized and conducted at a single institution, which may limit generalizability.
Participant Demographics
Patients were adults aged 18 to 75 with histologically confirmed metastatic or locally advanced inoperable colorectal cancer.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website